Literature DB >> 12011125

Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia.

Stefan Fröhling1, Silvia Skelin, Claudia Liebisch, Claudia Scholl, Richard F Schlenk, Hartmut Döhner, Konstanze Döhner.   

Abstract

PURPOSE: To prospectively compare cytogenetic and molecular cytogenetic analysis for the detection of the most relevant chromosome abnormalities in a large series of patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: Two hundred forty consecutive adult patients with AML entered onto the multicenter treatment trial AML HD93 were studied. Chromosome banding and fluorescence in situ hybridization (FISH) applying a comprehensive set of genomic DNA probes were performed in a single reference laboratory.
RESULTS: Two cases of inv(16), three cases of t(11q23), and three cases of t(8;21)var were only detected by molecular cytogenetics. By FISH, aberrations were identified in three cases with normal karyotypes: inv(16), -Y (in a patient with low metaphase yield on chromosome banding) and a 12p microdeletion. Additional aneuploidies, in particular +8q and +11q, were diagnosed by FISH; however, virtually all these aberrations occurred in patients with complex karyotypes or as an additional abnormality in leukemias with an AML-specific translocation. Finally, aberrations were detected by FISH in eight of 14 patients with no assessable metaphases.
CONCLUSION: In most cases of AML, conventional cytogenetic study reliably detects chromosomal abnormalities, and this method should not be replaced by FISH. FISH should be used as a complementary method for the detection of more subtle abnormalities, such as inv(16) and t(11q23), in all patients with newly diagnosed AML and for suspected t(8;21)var. Furthermore, molecular cytogenetics using this comprehensive set of DNA probes provides a valuable diagnostic tool for patients with poor chromosome morphology, low or no yields of metaphase cells, or both.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12011125     DOI: 10.1200/JCO.2002.08.155

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  18 in total

1.  Ring/marker chromosome derived from chromosome 7 in childhood acute megakaryoblastic leukemia with monosomy 7.

Authors:  Hisanori Fujino; Naoto Fujita; Kazuko Hamamoto; Satoshi Oobu; Makoto Kita; Atsushi Tanaka; Hiroshi Matsubara; Ken-Ichiro Watanabe; Toshio Heike; Souichi Adachi
Journal:  Int J Hematol       Date:  2010-09-01       Impact factor: 2.490

2.  BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia.

Authors:  Gu-Sheng Tang; Jun Wu; Min Liu; Hui Chen; Shen-Glan Gong; Jian-Min Yang; Xiao-Xia Hu; Jian-Min Wang
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

Review 3.  FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes
Journal:  Cancer       Date:  2011-02-11       Impact factor: 6.860

4.  KIT proto-oncogene exon 8 deletions at codon 419 are highly frequent in acute myeloid leukaemia with inv(16) in Indian population.

Authors:  Syed Rizwan Hussain; Hena Naqvi; Farzana Mahdi; Cherry Bansal; Sunil G Babu
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

5.  Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation.

Authors:  Min Fang; Barry Storer; Brent Wood; Boglarka Gyurkocza; Brenda M Sandmaier; Frederick R Appelbaum
Journal:  Cancer       Date:  2011-09-16       Impact factor: 6.860

Review 6.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

7.  Serum levels of FAK and some of its effectors in adult AML: correlation with prognostic factors and survival.

Authors:  Mona G El-Sisi; Sara M Radwan; Alia M Saeed; Hala O El-Mesallamy
Journal:  Mol Cell Biochem       Date:  2021-01-28       Impact factor: 3.396

8.  Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.

Authors:  Sylvain Mareschal; Anna Palau; Johan Lindberg; Philippe Ruminy; Christer Nilsson; Sofia Bengtzén; Marie Engvall; Anna Eriksson; Anne Neddermeyer; Vinciane Marchand; Monika Jansson; My Björklund; Fabrice Jardin; Mattias Rantalainen; Andreas Lennartsson; Lucia Cavelier; Henrik Grönberg; Sören Lehmann
Journal:  Blood Adv       Date:  2021-02-23

Review 9.  Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.

Authors:  Gerald B W Wertheim; Elizabeth Hexner; Adam Bagg
Journal:  Mol Diagn Ther       Date:  2012-12       Impact factor: 4.074

10.  Limited Utility of Fluorescence In Situ Hybridization for Recurrent Abnormalities in Acute Myeloid Leukemia at Diagnosis and Follow-up.

Authors:  Ferrin C Wheeler; Annette S Kim; Claudio A Mosse; Aaron C Shaver; Ashwini Yenamandra; Adam C Seegmiller
Journal:  Am J Clin Pathol       Date:  2018-03-29       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.